Patents by Inventor Xun Zhao
Xun Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117007Abstract: The present invention relates to a proliferation enhancer. The enhancer comprises a protein molecule capable of initiating the cellular STATS and/or STAT3 signaling pathway and comprising the intracellular domain, the transmembrane domain and the extracellular domain. The present invention further relates to a lymphocyte expressing the proliferation enhancer and the use thereof as an immunotherapy drug.Type: ApplicationFiled: February 10, 2022Publication date: April 11, 2024Inventors: Zhuo HUANG, Yanni Lin, Xun ZHAO, Xiaocui ZHENG
-
Publication number: 20240067673Abstract: A modified nucleoside or nucleotide, the 3?-OH of the modified nucleoside or nucleotide being reversibly blocked; meanwhile, the present invention also relates to a kit comprising the nucleoside or nucleotide, and a sequencing method based on the nucleoside or nucleotide.Type: ApplicationFiled: October 21, 2021Publication date: February 29, 2024Inventors: Xun XU, Bo TENG, Wenwei ZHANG, Ao CHEN, Handong LI, Shengyi YAN, Shitian ZHUO, Liang SHEN, Yonghui ZHANG, Nanfeng GAO, Jie ZHAO, Sha LIAO
-
Patent number: 11839607Abstract: A memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application thereof are provided. The cocrystal salt of the invention is memantine paroxetine sulfate hydrate. Its mechanism of action is 5-HT inhibitor and NMDA receptor antagonist. It is a multi-target drug. The preliminary pharmacokinetic experiments showed that the main pharmacokinetic parameters of cocrystal salt and memantine, such as T1/2, Tmax, Cmax and AUC(0-?), were significantly different. The results also showed that cocrystal salt could improve drug absorption, blood drug concentration, bioavailability and curative effect. This provides a material basis for reducing dosage and adverse drug reactions. In addition to that the cocrystal salt of this invention can be used as a multi-target drug, it can also combine with other drugs of different action mechanisms to form compound preparations or be used in combination, so as to obtain unexpected clinical efficacy.Type: GrantFiled: February 22, 2019Date of Patent: December 12, 2023Assignee: HEFEI KEDA BIO-TECHNOLOGY CO. LTDInventors: Ke Wang, Qianliu Cheng, Zonggui Wang, Yan Geng, Xun Zhao
-
Publication number: 20230040256Abstract: An image coloring method includes: acquiring first color a priori information about an image-to-be-colored; transforming the first color a priori information to obtain second color a priori information aligned with the image-to-be-colored; downsampling the image-to-be-colored to obtain a first image feature; performing modulation coloring processing on the first image feature based on the second color a priori information to obtain a second image feature; and upsampling the second image feature based on the second color a priori information to obtain a first colored image, where the first colored image is aligned with the image-to-be-colored.Type: ApplicationFiled: October 21, 2022Publication date: February 9, 2023Inventors: Yanze WU, Yu LI, Xintao WANG, Honglun ZHANG, Xun ZHAO, Ying SHAN
-
Publication number: 20210038590Abstract: A memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application thereof are provided. The cocrystal salt of the invention is memantine paroxetine sulfate hydrate. Its mechanism of action is 5-HT inhibitor and NMDA receptor antagonist. It is a multi-target drug. The preliminary pharmacokinetic experiments showed that the main pharmacokinetic parameters of cocrystal salt and memantine, such as T1/2, Tmax, Cmax and AUC(0-?), were significantly different. The results also showed that cocrystal salt could improve drug absorption, blood drug concentration, bioavailability and curative effect. This provides a material basis for reducing dosage and adverse drug reactions. In addition to that the cocrystal salt of this invention can be used as a multi-target drug, it can also combine with other drugs of different action mechanisms to form compound preparations or be used in combination, so as to obtain unexpected clinical efficacy.Type: ApplicationFiled: February 22, 2019Publication date: February 11, 2021Applicant: HEFEI KEDA BIO-TECHNOLOGY CO. LTDInventors: Ke WANG, Qianliu CHENG, Zonggui WANG, Yan GENG, Xun ZHAO
-
Publication number: 20190032359Abstract: Provided is a solar umbrella. The solar umbrella includes: solar cells packaged on umbrella cloth; umbrella ribs configured for supporting the umbrella cloth; a line concentration device mounted on the umbrella ribs. The line concentration device has sockets. The solar cells are connected to the sockets of the line concentration device.Type: ApplicationFiled: September 28, 2018Publication date: January 31, 2019Inventors: Bo JIANG, Yanpeng JU, Xun ZHAO
-
Patent number: 8833149Abstract: A piston fuel injector detecting device, comprising a base (1), a perspective platform (2), an observation cover (3), a sliding groove (4), an adjusting handle (5), a conducting wire column (6), a supporting plate (7), a tact switch (8), a limit plate (9), an infrared-ray emitting tube (10), an illuminating device (11) and a positioning pin (12), wherein the base (1) is connected with the perspective platform (2) and the positioning pin (12); the perspective platform (2) is connected with the observation cover (3) which is provided with the sliding groove (4); the adjusting handle (5) is connected with the observation cover (3); the conducting wire column (6) is vertically connected with the base (1) and is connected with the supporting plate (7) which is provided with the tact switch (8); the conducting wire column (6) is connected with the limit plate (9) which is connected with the infrared-ray emitting tube (10) and the illuminating device (11).Type: GrantFiled: December 3, 2010Date of Patent: September 16, 2014Assignee: Dalian Dexin M & E Technology Engineering Co., Ltd.Inventors: Xun Zhao, Yuejin Huang
-
Publication number: 20110158932Abstract: Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arteriosclerosis, high blood pressure, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty, intermittent claudication, dyslipidemia post-prandial lipidemia or xanthoma.Type: ApplicationFiled: December 8, 2008Publication date: June 30, 2011Inventors: Jian-Dong Jiang, Jing Wei, Wei-Jia Kong, Li-Xun Zhao, Dan-Qing Song
-
Publication number: 20080081781Abstract: Methods and compositions containing a berberine compound or berberine related or proto-berberine or derivative compound are provided for the prevention and treatment of metabolic and cardiovascular disorders including metabolic syndrome, hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension and elevated cholesterol in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of metabolic syndrome, hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension and elevated cholesterol.Type: ApplicationFiled: April 6, 2007Publication date: April 3, 2008Inventors: Arnold Lippa, Jian-Dong Jiang, Jing Wei, Wei-Jia Kong, Li-Xun Zhao, Dan-Qing Song
-
Publication number: 20060223838Abstract: Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arteriosclerosis, high blood pressure, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty, intermittent claudication, dyslipidemia post-prandial lipidemia or xanthoma.Type: ApplicationFiled: September 16, 2005Publication date: October 5, 2006Inventors: Jian-Dong Jiang, Jing Wei, Wei-Jia Kong, Li-Xun Zhao, Dan-Qing Song
-
Publication number: 20030064061Abstract: Recombinant Bcr-Abl polypeptides that form a stable &agr;-helical structure; nucleic acids encoding recombinant Bcr-Abl polypeptides; methods of identifying or designing inhibitors of Bcr-Abl oligomerization and methods of inhibiting Bcr-Abl oligomerization in cells and in individuals in need of inhibiting Bcr-Abl oligomerization, such as individuals who have developed or are at risk of developing chronic myelogenous leukemia or acute lymphoblastic leukemia.Type: ApplicationFiled: July 9, 2002Publication date: April 3, 2003Applicant: Whitehead Institute for Biomedical ResearchInventors: Xun Zhao, Saghi Ghaffari, Harvey F. Lodish, Vladimir N. Malashkevich, Peter S. Kim
-
Publication number: 20010043931Abstract: A method of identifying a drug that inhibits the RSV membrane fusion machinery, such as the HRSV membrane fusion machinery; drugs that bind the N-helix coiled-coil of HRSV, particularly the N-helix coiled-coil pocket, and, thus, inhibit HRSV infection of cells, such as human cells; methods of inhibiting (partially or totally) HRSV infection of an individual; anitbodies that bind to the N-helix coiled-coil region of HRSV F1; and pharmaceutical compositions comprising HRSV infection neutralizing antibodies.Type: ApplicationFiled: December 5, 2000Publication date: November 22, 2001Applicant: Whitehead Institute for Biomedical ResearchInventors: Xun Zhao, Mona Singh, Vladimir Malashkevich, Peter S. Kim
-
Patent number: PP31244Abstract: A new and distinct cultivar of Nelumbo plant named ‘Zhijiang Qiuyue’, characterized by its upright plant habit; moderately vigorous growth habit; large medium green-colored leaves; freely flowering habit; and large pale yellow and green white-colored plated globose-shaped flowers that are positioned above the foliar plane on moderately strong and erect peduncles.Type: GrantFiled: September 17, 2018Date of Patent: December 17, 2019Assignee: Zhejiang Renwen Landscape Architecture Co., Ltd.Inventors: Xun Zhao, Yuchu Chen
-
Patent number: PP31245Abstract: A new and distinct cultivar of Nelumbo plant named ‘Buzeng Jielu’, characterized by its upright plant habit; moderately vigorous growth habit; large medium green-colored leaves; freely flowering habit; and large red purple-colored calathiform flowers that are positioned above the foliar plane on moderately strong and erect peduncles.Type: GrantFiled: September 17, 2018Date of Patent: December 17, 2019Assignee: Zhejang Renwen Landscape Architecture Co., Ltd.Inventors: Yuchu Chen, Xun Zhao